BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 29, 2001
View Archived Issues
Digene cleared to market test for STDs in Japan
Read More
Ester and Pharmacopeia collaborate on small-molecule neurological drug discovery
Read More
FDA accepts amendment to approvable letter for Xyrem from Orphan Medical
Read More
Potential new antipsychotic from Solvay combines D2 antagonism and 5-HT reuptake inhibition
Read More
Basic and clinical studies on aripiprazole discussed in Istanbul
Read More
Addition of oral morphine to standard therapy significantly improves symptoms in resistant OCD
Read More
Improvement in functional constipation demonstrated for NT-3 in controlled trial
Read More
Feasibility of different schedule of administration assessed for ET-743 in clinical trial
Read More
Vertex highlights Q3 2001 progress
Read More
Combinations of Janssen farnesyltransferase inhibitor with other chemotherapeutic agents
Read More
MGI Pharma updates Q3 developments
Read More
Preliminary analysis of phase II data for LY-355703 results in trial suspension
Read More
GenVec continues to make advances with gene-based drug candidates
Read More
EB-1089 exerts significant chemopreventive effect in animal model of hepatocarcinoma
Read More
Acapodene advances to next phase of clinical trials as prostate cancer preventive
Read More
AtheroGenics updates product developments during third quarter
Read More
LDL receptor upregulators emerge from joint Tularik/Sumitomo program
Read More
Dual M3 and 5-HT4 antagonists claimed in recent patent by Sanofi-Synthelabo
Read More
Sanofi-Synthelabo describes novel V1-selective agents and their use
Read More
Chemokine receptor modulators reportedly useful for HIV infection, etc.
Read More
PDE4-inhibitory heterocyclic carboxamides patented by Merck
Read More
Finnish labs identify alpha2 blockers for use in CNS disorders
Read More
Ningalin B analogues as MDR reversal agents reported by Scripps
Read More
Oral Ono-3403 effective in murine skin cancer model
Read More
BT-99-25, a nonantisense oligonucleotide, blocks cell cycle progression and induces apoptosis
Read More